Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISTAS: Volixibat for cholestatic pruritus in primary sclerosing cholangitis
2023-505764-11-00Phase 2Authorised
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing Volixibat with Placebo (2 arms). Primary endpoint: Mean change in Adult ItchRO score. Planned start Jun 2022; status: authorised.
02
Drugs
volixibat
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2023-505764-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505764-11-00.